Carlyle Group Inc. - 08 Feb 2024 Form 4 Insider Report for Jasper Therapeutics, Inc. (JSPR)

Reporting relationship: Former 10% Owner
Issuer ticker: JSPR
Reported as of: 08 Feb 2024
Net transaction value: +$2,460,500
SEC form: 4
Accepted by SEC: 12 Feb 2024, 18:23:53 UTC
Prior SEC filing: 03 Jan 2024
Next SEC filing: 02 Apr 2024
Source filing: View source filing
Reporting owner signature: The Carlyle Group Inc., By: /s/ Anne Frederick, Attorney-in-fact for John C. Redett, Chief Financial Officer

Key filing fact

Carlyle Group Inc. filed Form 4 for Jasper Therapeutics, Inc. (JSPR) on 12 Feb 2024.

Key facts

This page summarizes Carlyle Group Inc.'s Form 4 filing for Jasper Therapeutics, Inc. (JSPR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Feb 2024, 18:23.

Change

Previous filing in this sequence was filed on 03 Jan 2024.
Current net transaction value: +$2,460,500.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

JSPR transaction

Voting Common Stock

Purchase

Transaction value: $2,460,500
Shares: +190,000
Change %: +22%
Price: $12.95
Shares after: 1,066,189
Date: 08 Feb 2024
Ownership: See footnotes
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Carlyle Group Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

The amount of Voting Common Stock reported herein reflects a 1-for-10 reverse stock split effected by the Issuer on January 4, 2024.

Footnote F2

Reflects securities held of record by Abingworth Bioventures VII LP ("ABV VII"). ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII.

Footnote F3

The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV VII, but each disclaims beneficial ownership of such securities except to the extent of their pecuniary interest therein, if any.

SEC remarks

Exhibit 24 - Power of Attorney.